Top

Published in:

01-09-2017 | COMMENTARY

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas

Authors: Tim Heise, Ulrike Hövelmann, Leszek Nosek, Bettina Sassenfeld, Karen Margrete Due Thomsen, Hanne Haahr

Published in: Clinical Drug Investigation | Issue 9/2017

Excerpt

We are grateful to Dr. Srinivas for his thorough review of our data. He points out potential differences in the pharmacodynamic effects of insulin preparations between healthy people and people with diabetes and discusses several reasons for these differences, including insulin dose, effect of endogenous insulin, anti-insulin antibodies, and local injection site issues in people with diabetes [1]. …

Srinivas NR. Pharmacodynamics of insulin preparations administered in different subcutaneous injection sites: are there differences between healthy subjects versus diabetic patients? Clin Drug Investig. 2017. doi:10.1007/s40261-017-0538-8

Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Morschel L, Forst T. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016;18(10):962–72.CrossRefPubMed

Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51(10):1790–5.CrossRefPubMed

Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501–6.CrossRefPubMed

Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H. Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions. Clin Drug Investig. 2017;37(5):503–9.CrossRefPubMedPubMedCentral

Nosek L, Coester HV, Roepstorff C, Thomsen HF, Kristensen NR, Haahr H, et al. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. Clin Drug Investig. 2014;34(9):673–9.CrossRefPubMedPubMedCentral

Süsstrunk H, Morell B, Ziegler WH, Froesch ER. Insulin absorption from the abdomen and the thigh in healthy subjects during rest and exercise: blood glucose, plasma insulin, growth hormone, adrenaline and noradrenaline levels. Diabetologia. 1982;22:171–4.CrossRefPubMed

ter Braak E, Woodworth JR, Bianchi R, Cerimelle B, Erkelens DW, Thijssen JH, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996;19:1437–40.CrossRefPubMed

Koivisto VA, et al. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92:59–61.CrossRefPubMed

10.

Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5(2):77–91.CrossRefPubMed

11.

Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16:1592–7.CrossRefPubMed

12.

Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, Johnston DG. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol (Oxf). 1991;35(5):409–12.CrossRef

13.

Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005;27(2):210–5.CrossRefPubMed

14.

Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15:1484–93.CrossRefPubMed

15.

Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787–800.CrossRefPubMedPubMedCentral

16.

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (Onset 1). Diabetes Care. 2017.

17.

Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56(5):551–9.CrossRefPubMedPubMedCentral

18.

Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;30(6):CD012161.

19.

Henriksen JE, Djurhuus MS, Vaag A, Thye Ronn P, Knudsen D, Hother Nielsen O, et al. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia. 1993;36:752–8.CrossRefPubMed

Title: Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas
Authors: Tim Heise
Ulrike Hövelmann
Leszek Nosek
Bettina Sassenfeld
Karen Margrete Due Thomsen
Hanne Haahr
Publication date: 01-09-2017
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 9/2017
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-017-0539-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2017

Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study

Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece

Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy

Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?

Erratum to: Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men